Highest-materiality recent filing
CNS Pharma raises ~$22.5M in private placement at $2.30/sh; board change
Gross proceeds ~$22.5M from sale of 650K shares at $2.30/sh and pre-funded warrants for 9.14M shares at $2.299/warrant.
CNS Pharmaceuticals posts routine investor presentation; no material new disclosures
Company filed Form 8-K indicating it posted a March 2026 investor presentation on its website.
CNS Pharmaceuticals appoints Lynne Kelley as CMO; former CMO Sandra Silberman departs with severance
Lynne Kelley appointed CMO effective March 2, 2026; base salary $450K, target bonus 40%.
CNS Pharmaceuticals appoints Steve O'Loughlin as CFO; current CFO Downs moves to SVP Finance
Steve O'Loughlin appointed CFO effective March 2, 2026; base salary $450,000, target bonus 40% of base.
CNS Pharmaceuticals appoints Rami Levin as CEO effective January 1, 2026; John Climaco resigns
Rami Levin becomes CEO and President effective Jan 1, 2026; base salary $580,000, target bonus 50% of base, initial RSU grant of 19,000 shares.
Authorized common stock increased from 25M to 300M shares; preferred from 416,667 to 5M shares.
CNS Pharmaceuticals announces 1-for-12 reverse stock split effective July 22, 2025
Reverse split reduces outstanding shares from ~6.36M pre-split to ~529,829 post-split.
CNS Pharmaceuticals posts July 2025 investor presentation; no material new disclosures
No financial results, guidance, or operational milestones disclosed.
CNS Pharmaceuticals raises ~$5.0M in public offering of stock and warrants
Offering of 325,000 shares, 3,627,570 pre-funded warrants, and 3,952,570 common warrants.
CNS Pharmaceuticals releases April 2025 investor presentation; no specific news disclosed
Presentation dated April 2025 furnished under Regulation FD for investor meetings.
CNS Pharmaceuticals regains Nasdaq compliance; subject to one-year monitoring period
Nasdaq letter dated March 31, 2025 confirms regained compliance with $1.00 bid price rule.
CNS Pharmaceuticals ups ATM sales capacity to $43.5M from $30.2M; $23.75M raised so far
Company increased aggregate sales price under A.G.P. Sales Agreement to $43.5M on March 20, 2025.
CNS Pharmaceuticals announces 1-for-50 reverse stock split effective Feb 21, 2025
Reverse stock split at 1-for-50 ratio effective Feb 21, 2025; shares outstanding reduced from ~136.93M to ~2.74M.
CNS Pharmaceuticals sold 17.5M shares via ATM; shares outstanding now 74.96M
Sold 17,475,827 shares under at-the-market agreement since last 10-Q (Sept 30, 2024).
Virtual analyst and investor day held on December 11, 2024.
CNS Pharma stockholders approve reverse split (1:2 to 1:50) and warrant repricing
Reverse split authorized at ratio between 1-for-2 and 1-for-50; passed with 7,873,677 votes for, 3,121,776 against, 314,908 abstain.
Company received Nasdaq deficiency notice on Sept 12, 2024 for bid price below $1.00 for 30 consecutive days.
Gross proceeds ~$3M from sale of 3.7M common shares and pre-funded warrants for 13.9M shares at $0.17/share.
CNS Pharma faces Nasdaq delisting for bid price deficiency; hearing Nov 5
Received Nasdaq notice on Sept 12, 2024, for failing minimum $1.00 bid price for 30 consecutive days.
CNS Pharma receives Nasdaq minimum bid deficiency; ineligible for cure due to reverse splits
Nasdaq notified CNS Pharma on Sept 12, 2024 that common stock failed to maintain $1.00 minimum bid for 30 consecutive days.
CNS Pharma regains Nasdaq compliance; subject to one-year Mandatory Panel Monitor
On Sep 10, 2024, Nasdaq confirmed CNS Pharma has demonstrated compliance with the $2.5M stockholders' equity requirement; delisting matter closed.
CNS Pharmaceuticals regains Nasdaq equity compliance after $9.9M share sale
Shareholders' equity exceeds $5.0M, above Nasdaq's $2.5M minimum for continued listing.
CNS Pharmaceuticals in-licenses TPI 287 from Cortice for brain cancer treatment
CNS Pharmaceuticals entered an exclusive license agreement with Cortice Biosciences for TPI 287, a blood-brain barrier permeable abeotaxane, covering U.S., Canada, Mexico, and Japan.
CNS Pharma boosts ATM equity facility from $5.2M to $30.2M; $5.19M already sold
On July 30, 2024, CNS Pharmaceuticals increased the aggregate sales price under its ATM agreement to $25M, for a total of $30.2M including original $5.2M.
CNS Pharma enters $5.2M ATM offering with A.G.P.; warrants repriced
Entered Sales Agreement with A.G.P. for at-the-market offering of up to $5.2M common stock; commission 3.0%.
CNS Pharmaceuticals gets final Nasdaq extension to Aug 12 for equity compliance
Nasdaq Panel granted extension until August 12, 2024 to meet $2.5M stockholders' equity requirement.
CNS Pharma regains Nasdaq bid price compliance; still faces equity rule delisting risk
Received Nasdaq letter on July 5, 2024 confirming bid price compliance (closing bid >=$1.00 for 20 consecutive business days through July 3).
CNS Pharmaceuticals regains Nasdaq bid price compliance after 20-day period
Received Nasdaq deficiency letter Feb 27, 2024 for bid price below $1.00 for 30 consecutive days.
CNS Pharmaceuticals announces $1.98M registered direct offering and private placement
Sold 1,425,000 shares at $1.39 per share with common warrants at $1.26 exercise price.
CNS Pharmaceuticals raises ~$1.39M in registered direct offering and private placement
Priced 568,000 common shares plus warrants for 568,000 shares at $2.45 per unit, gross proceeds ~$1.39M.
CNS Pharmaceuticals files 8-K/A to add legal opinion omitted from prior filing
Amendment adds Exhibit 5.1 (ArentFox Schiff legal opinion) inadvertently omitted from June 14 8-K.
CNS Pharmaceuticals prices $1.37M registered direct offering and private placement
Offering of 366,000 shares (or pre-funded warrants) at $3.75/share, with common warrants exercisable at $3.62.
1-for-50 reverse stock split effective 4:01 PM ET June 4, 2024; trading on split-adjusted basis from June 5, 2024 under symbol CNSP.
CNS Pharma Q1 net loss $3.5M; Berubicin GBM trial topline data H1 2025
Net loss $3.5M for Q1 2024, vs $4.9M in Q1 2023; R&D expense down to $2.4M from $3.6M.
On May 4, 2026, Jerzy (George) Gumulka resigned as a member of the Company’s Board of Directors (the “Board”) . Mr. Gumulka’s resignation from the Board was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
On May 4, 2026, the Board agreed to appoint Michal Fisher as an independent member of the Company’s Board.
Max materiality 0.85 · Median 0.65 · Most common event other_material